

**EANM Focus 5, the International Conference on
“Molecular Imaging and Theranostics in Prostate Cancer
- the Future Begins Today”**
February 2-4, 2023 / Seville, Spain

Scientific Programme

Thursday, February 2, 2023

Track 1 – Staging of Intermediate and High-Risk Prostate Cancer

Chairpersons: Anders Bjartell, Evis Sala, Stefano Fanti

<i>Time</i>	<i>Presentation Title</i>	<i>Speaker</i>
08:30-08:40	Entering the Future (Welcome to all Participants)	Rudi Dierckx
08:40-08:50	Outcomes of Focus 1 in 2018	Stefano Fanti
08:50- 09:00	Opening & Objectives	Daniela E. Oprea-Lager
09:00-09:25	Staging Prostate Cancer: Still a Clinical Unmet Need?	Anders Bjartell
09:30-09:55	Staging Prostate Cancer: The Evolving Role of Radiology	Evis Sala
10:00-10:25	Staging Prostate Cancer: The Evolving Role of Nuclear Medicine	Stefano Fanti
11:00-11:15	Controversy: Should Molecular Imaging Fully Replace Conventional Imaging?	Roman Sosnowski
11:15-11:22	<i>In Favour</i>	Irene Burger
11:23-11:30	<i>Against</i>	Evis Sala
11:30-11:45	What Is the Evidence?	Igle de Jong
11:45-12:00	Questions & Answers	
12:00-13:00	Consensus on Imaging for Staging Intermediate and High Risk Prostate Cancer	Stefano Fanti, Daniela E. Oprea-Lager

Track 2 – Imaging of Biochemical Recurrence in Prostate Cancer

Chairpersons: Jochen Walz, Valeria Panebianco, Andrei Iagaru

<i>Time</i>	<i>Presentation Title</i>	<i>Speaker</i>
14:00-14:25	Biochemical Recurrence in Prostate Cancer: Still a Clinical Unmet Need?	Jochen Walz
14:30-14:55	Biochemical Recurrence in Prostate Cancer: The Evolving Role of Diagnostic Imaging	Valeria Panebianco
15:00-15:25	Biochemical Recurrence in Prostate Cancer: The Evolving Role of Nuclear Medicine	Andrei Iagaru
16:00-16:22	Does Early Detection of Biochemical Recurrence Offer Survival Benefit?	Bertrand Tombal
16:23-16:45	Impact of Changing Clinical Management in Biochemical Recurrence Setting	Derya Tilki
16:45-17:00	Questions & Answers	
17:00-18:00	Consensus on Imaging for Biochemical Recurrence of Prostate Cancer	Andrei Iagaru, Daniela E. Oprea-Lager

Friday, February 3, 2023

Track 3 - Imaging of Advanced Prostate Cancer

Chairpersons: Karim Fizazi, Nina Tunariu, Irene Burger

<i>Time</i>	<i>Presentation Title</i>	<i>Speaker</i>
09:00-09:25	Advanced Prostate Cancer: Still a Clinical Unmet Need?	Karim Fizazi
09:30-09:55	Advanced Prostate Cancer: The Evolving Role of Radiology	Nina Tunariu
10:00-10:25	Advanced Prostate Cancer: The Evolving Role of Nuclear Medicine	Irene Burger
11:00-11:15	Controversy: Do We Need Next-Generation Imaging Modalities in Advanced Prostate Cancer?	Joe O'Sullivan
11:15-11:22	<i>In Favour</i>	Marnix Lam
11:23-11:30	<i>Against</i>	Valeria Panebianco
11:30-11:45	What Is the Evidence?	Derya Yakar
11:45-12:00	Questions & Answers	
12:00-13:00	Consensus on Imaging of Advanced Prostate Cancer	Joe O'Sullivan, Daniela Oprea-Lager

Track 4 – Therapy of Advanced Prostate Cancer

Chairpersons: Silke Gillessen, Ken Herrmann, Oliver Sartor

<i>Time</i>	<i>Presentation Title</i>	<i>Speaker</i>
14:00-14:25	Advanced Prostate Cancer: Oncological Therapeutic Options	Silke Gillessen
14:30-14:55	Advanced Prostate Cancer: PSMA Theranostics Options	Ken Herrmann
15:00-15:25	Therapy of Advanced Prostate Cancer: Still a Clinical Unmet Need?	Oliver Sartor
16:00-16:15	Does PSMA Theranostics Offer (Enough) Survival Benefit in Advanced Prostate Cancer?	Maria De Santis
16:15-16:30	PSMA Theranostics - The Urologist's Perspective	Alberto Briganti
16:30-16:45	PSMA Theranostics - The Medical Oncologist's Perspective	Oliver Sartor
16:45-17:00	Questions & Answers	
17:00-18:00	Consensus on Therapy of Advanced Prostate	Silke Gillessen, Daniela E. Oprea-Lager

Saturday, February 4, 2023

Track 5 – Theranostics in Prostate Cancer – A New Kid on the Block

Chairpersons: Daniela E. Oprea Lager, Stefano Fanti

<i>Time</i>	<i>Presentation Title</i>	<i>Speaker</i>
09:00-09:20	Development of Radiopharmaceuticals for Theranostics Applications	Sandra Heskamp
09:20-09:40	Alpha, Beta or Tandem Therapy: Good, Better, the Best?	Mike Sathekge
09:40-10:00	Current and Future Indications for Theranostics Applications in Prostate Cancer	Marnix Lam
10:00-10:20	Radiation Dosimetry for Theranostic Applications in Prostate Cancer	Uta Eberlein
10:50-11:15	Clinical Trials on Theranostics in Prostate Cancer	Louise Emmett
11:15-11:35	Clinical Trials with New Oncologic Agents in Prostate Cancer	Karim Fizazi
11:35-11:55	Combining Theranostics with Radiotherapy: A New Direction?	Barbara Alicja Jereczek-Fossa
11:55-12:15	PET/MRI: A New Approach for Functional and Morphological Imaging?	Ken Herrmann
12:15-12:30	Consensus on "Relevant Factors to Build a Consensus"	all panellists (Chairpersons: Jolanta Kunikowska, Anders Bjartell)

12:30-12:50 **Summary of Results and Debate with all Participants**

12:50-13:00 **Future Directions & Closing Remarks**

all panellists (Chairpersons:
Daniela E. Oprea-Lager,
Stefano Fanti)
Rudi Dierckx,
Daniela E. Oprea-Lager